Anaxsys Technology Limited, a Keele, UK-based developer of a suite of devices which allow diagnosis and monitoring of a variety of diseases by analysing the humidity profile of the breath, has recently raised £500,000 in a funding round led by the Early Advantage Fund.The new capital will allow the company to conduct clinical trials prior to launching its first product, called R8, later in 2010.
The core technology developed by Anaxsys has important applications across many sectors of healthcare, including screening for lung cancer, the postoperative monitoring of patients and in the diagnosis and monitoring of asthma.
The £8m Early Advantage Fund, which is managed by Birmingham-based Midven and backed by Advantage West Midlands and the European Regional Development Fund, committed £125,000.
FinSMEs
14/05/2010